Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1992 1
2002 1
2004 1
2006 2
2010 1
2011 4
2012 1
2013 1
2014 3
2015 5
2016 1
2017 2
2018 4
2019 1
2021 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Mateos MV, et al. N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12. N Engl J Med. 2018. PMID: 29231133 Free article. Clinical Trial.
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Rodriguez Macías G, Chiou TJ, Quiel D, Aoun M, Navarro Matilla MB, de la Serna J, Milliken S, Murphy J, McNeil SA, Salaun B, Di Paolo E, Campora L, López-Fauqued M, El Idrissi M, Schuind A, Heineman TC, Van den Steen P, Oostvogels L; Zoster-039 study group. Dagnew AF, et al. Among authors: woszczyk d. Lancet Infect Dis. 2019 Sep;19(9):988-1000. doi: 10.1016/S1473-3099(19)30163-X. Epub 2019 Aug 6. Lancet Infect Dis. 2019. PMID: 31399377 Clinical Trial.
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Adès L, Girshova L, Doronin VA, Díez-Campelo M, Valcárcel D, Kambhampati S, Viniou NA, Woszczyk D, De Paz Arias R, Symeonidis A, Anagnostopoulos A, Munhoz EC, Platzbecker U, Santini V, Fram RJ, Yuan Y, Friedlander S, Faller DV, Sekeres MA. Adès L, et al. Among authors: woszczyk d. Blood Adv. 2022 Sep 13;6(17):5132-5145. doi: 10.1182/bloodadvances.2022007334. Blood Adv. 2022. PMID: 35728048 Free PMC article. Clinical Trial.
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Verstovsek S, Al-Ali HK, Mascarenhas J, Perkins A, Vannucchi AM, Mohan SR, Scott BL, Woszczyk D, Koschmieder S, García-Delgado R, László R, McGreivy JS, Rothbaum WP, Kiladjian JJ. Verstovsek S, et al. Among authors: woszczyk d. Future Oncol. 2022 Nov 23. doi: 10.2217/fon-2022-0901. Online ahead of print. Future Oncol. 2022. PMID: 36416118 Free article. Review.
Histopathological diagnosis of microscopic colitis.
Liszka Ł, Woszczyk D, Pajak J. Liszka Ł, et al. Among authors: woszczyk d. J Gastroenterol Hepatol. 2006 May;21(5):792-7. doi: 10.1111/j.1440-1746.2006.04332.x. J Gastroenterol Hepatol. 2006. PMID: 16704525 Review.
The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age.
Tyczyńska A, Krzempek MK, Cortez AJ, Jurczyszyn A, Godlewska K, Ciepłuch H, Subocz E, Hałka J, Kulikowska de Nałęcz A, Wiśniewska A, Świderska A, Waszczuk-Gajda A, Drozd-Sokołowska J, Guzicka-Kazimierczak R, Wiśniewski K, Porowska A, Knopińska-Posłuszny W, Kłoczko J, Rzepecki P, Woszczyk D, Symonowicz H, Basak GW, Zdziarska B, Jamroziak K, Zaucha JM. Tyczyńska A, et al. Among authors: woszczyk d. Cancers (Basel). 2023 Jul 2;15(13):3469. doi: 10.3390/cancers15133469. Cancers (Basel). 2023. PMID: 37444579 Free PMC article.
rs2072135, a low-penetrance variant for chronic lymphocytic leukaemia?
Sava GP, Speedy HE, Di Bernardo MC, Deaglio S, Karabon L, Frydecka I, Woszczyk D, Rossi D, Gaidano G, Mansouri L, Smedby KE, Juliusson G, Rosenquist R, Catovsky D, Houlston RS. Sava GP, et al. Among authors: woszczyk d. Br J Haematol. 2013 Jul;162(2):221-8. doi: 10.1111/bjh.12366. Epub 2013 May 14. Br J Haematol. 2013. PMID: 23668599 Free article.
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk.
Sava GP, Speedy HE, Di Bernardo MC, Dyer MJ, Holroyd A, Sunter NJ, Marr H, Mansouri L, Deaglio S, Karabon L, Frydecka I, Jamroziak K, Woszczyk D, Juliusson G, Smedby KE, Jayne S, Majid A, Wang Y, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS. Sava GP, et al. Among authors: woszczyk d. Leukemia. 2015 Mar;29(3):748-51. doi: 10.1038/leu.2014.311. Epub 2014 Nov 3. Leukemia. 2015. PMID: 25363670 Free PMC article. No abstract available.
30 results